Call 413.540.1234 to
schedule an appointment
CONCERN/EAP: 413.534.2625
Billing questions? Call: 413.540.1212
CRISIS: 413.733.6661

Health Policy & Advocacy
Resources
Basic InformationMore InformationLatest News
FDA Warns of Deaths Tied to Tainted Synthetic PotWhere Are Opioid Painkillers Prescribed the Most?In the ICU, Patients' Relatives Often Mum About Care ConcernsResetting E-Prescriptions for Opioids Helps Curb Use: StudyHealth Tip: If You're 45 or Older, Get Screened for Colorectal CancerRed Cross Issues Nationwide Call for Blood DonationsDoctor Burnout Widespread, Helps Drive Many Medical ErrorsWarming Climate, More AC -- and More Unhealthy Smog AheadEven at 'Safe' Levels, Air Pollution May Boost Diabetes RiskDeath Certificate Data May Miss Many Opioid ODs: StudyRaise the Bar on CPR, Heart Group SaysWhen DEA Cracked Down on Opioids, Abusers Moved to Black Market: StudyStigma of Safe Needle Exchanges Lingers Despite Opioid EpidemicAHA: Drones a Lifesaver for Cardiac Arrest Patients?Millions Die Worldwide Each Year for Lack of Quality CareTips for Handling a Medical EmergencyAHA: Lifesaving Info Not Always a 911 Call AwayMany, But Not All, Hospitals Require Flu Shots for StaffersCancer Care Twice as Costly in U.S. Versus CanadaAHA: Health Concerns Haunt Puerto Rico as New Hurricane Season BeginsPot, Opioids Now Rival Alcohol as Factor in Driver DeathsThe ER or Urgent Care?Trumps Signs Bill Allowing Terminal Patients to Try Unproven MedicinesTough State Drunk Driving Laws Save LivesE-Cigarettes Don't Help Smokers Quit, But Cash MightSmall World? Not With One-Quarter Obese by 2045A Pill to Protect You From the Sun? Don't Believe It, FDA SaysMost Hospitals Aren't Ready for Mass Tragedies, ER Docs SayAHA: Making America's Doctors Look More Like AmericaLanguage Used in Medical Record Can Affect Patient CareNonprofit Manufacturer Could Keep Generic Drug Costs DownOpioid Makers' Perks to Docs Tied to More PrescriptionsFDA Targets Clinics Offering Unapproved Stem Cell TherapiesLittle 'Quit-Smoking' Help at U.S. Mental Health CentersIs Testing for Zika in U.S. Blood Supply Worth the Cost?'Smoke-Free' Rooms Still Loaded With Smoke Residues, Study FindsAHA: Smoke-Free Laws Do Seem to Help Young Adults' HeartsAHA: Poverty Levels Key to States' Performance on Heart DiseaseSimple Drug Packaging Change Could Save Toddlers' LivesFDA Cracks Down on Dangerous E-Cig Liquids That Resemble Cookies, CandyNew Clinic Satisfaction Tool Provides Real-Time FeedbackUnused Meds? Saturday Is National Drug Take Back DayA Doctor's Age May Matter With Emergency SurgeryPatients Prefer Doctors Who Engage in Face-to-Face VisitsU.S. Better Able to Tackle Health Emergencies: ReportFirst Opioid Lawsuit Targeting Pharmacy Benefit ManagersMost Doctors' Offices Don't Offer Flexibility for UninsuredSafety Info for Opioids Found LackingNonoptimized Drug Therapy Costs More Than $500 Billion AnnuallyFDA Cracks Down on Caffeine-Loaded Supplements
Questions and AnswersLinksBook Reviews
Related Topics

Early Studies Often Show Exaggerated Treatment Effect


HealthDay News
Updated: Feb 27th 2018

new article illustration

TUESDAY, Feb. 27, 2018 (HealthDay News) -- Trials to evaluate drugs or devices used to treat chronic medical conditions that are published early in the chain of evidence often show an exaggerated treatment effect compared with subsequent trials, according to research published online Feb. 21 in the Mayo Clinical Proceedings.

Fares Alahdab, M.D., from the Mayo Clinic in Rochester, Minn., and colleagues assessed meta-analyses (MAs), published between Jan. 1, 2007, and June 23, 2015, in the 10 general medical journals with highest impact factor to identify randomized controlled trials (RCTs) evaluating a drug or device in patients with chronic medical conditions.

The researchers identified 70 MAs that had included a total of 930 RCTs with an average follow-up of 24 months. An exaggerated early effect (defined as the proportion of MAs with largest effect or heterogeneity in the first two trials) was seen in 37 percent of MAs. On average, the effect size in the early trials was 2.67 times larger than the overall pooled effect size (ratio of relative effects, 2.67). There were no significant associations between the presence of exaggerated effect and trial size; number of events; length of follow-up; intervention duration; number of study sites; inpatient versus outpatient setting; funding source; stopping a trial early; adequacy of random sequence generation, allocation concealment, or blinding; loss to follow-up; or the test for publication bias.

"Considering the increasing morbidity and mortality of chronic medical conditions, decision makers should act on early evidence with caution," the authors write.

Abstract/Full Text
Editorial